Mycophenolate Mofetil Versus Cyclophosphamide for Initial Therapy In Childhood-Onset Proliferative Lupus Nephritis: A Prospective, Multicenter,Randomized Trial

This is an open-label, multicenter, randomized, noninferiority study that compared the efficacy and safety of oral mycophenolate mofetil (MMF) plus glucocorticoids versus intravenous cyclophosphamide (IVC) plus glucocorticoids as induction therapy for renal remission in newly diagnosed pediatric patients with proliferative lupus nephritis and either urine protein-creatinine ratio (UPCR) ≥ 1000 mg/g or 24-hour urinary protein excretion > 25 mg/kg.